Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
GAITHERSBURG, Md., May 11, 2017 -- Novavax, Inc. (Nasdaq:NVAX), today announced that Dr. James F. Cummings has been promoted to Vice President, Clinical Development and Translational Medicine. Dr. Cummings joined Novavax as Senior Director of Clinical Development in September 2015, with a specific focus on advancing Novavax’ programs within emerging infectious disease. Previously, Dr. Cummings served as the Director for Global Emerging Infections Surveillance and Response System (GEIS) at the Armed Forces Health Surveillance Branch (AFHSB), Director, Translational Medicine Branch & Division of Regulated Activities at Walter Reed Army Institute of Research (WRAIR) and Consultant to the U.S. Army Surgeon General for all Medical Research and Development.
“In his short tenure at the company, James has shown his ability to constructively organize, motivate and manage complex development programs,” said Stanley C. Erck, President and CEO. “His demonstrated expertise in product development and leadership capabilities earned James the appointment of Project Lead for our nanoparticle influenza vaccine candidate development program, and promotion to Vice President. I am thrilled to congratulate James for his successes here at Novavax.”
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Director, Investor Relations [email protected] 240-268-2000
